Pictured: AbbVie's headquarters in California/iStock, Michael Vi

图片：艾伯维在加利福尼亚州的总部/伊斯托克，迈克尔六世

AbbVie on Thursday announced it entered into two exclusive option and license agreements with Seattle-based Umoja Biopharma to develop multiple in-situ CAR-T therapies targeting various cancers.

AbbVie周四宣布，它与总部位于西雅图的Umoja Biopharma签订了两项独家选择和许可协议，以开发针对各种癌症的多种原位CAR-T疗法。

The companies did not provide a specific breakdown of the financial terms of each deal. However, they said that the combined agreements could yield Umoja up to $1.44 billion in option exercise fees and developmental and regulatory milestones, on top of upfront payments and equity investments from AbbVie.

这些公司没有提供每笔交易财务条款的具体明细。然而，他们表示，除了艾伯维（AbbVie）的预付款和股权投资外，这些合并协议还可能产生多达14.4亿美元的期权行权费以及发展和监管里程碑。

Umoja will also be eligible for sales-based milestones and tiered royalties on net worldwide sales..

Umoja还将有资格获得基于销售的里程碑和全球净销售额的分层版税。。

“We believe that in-situ CAR-T cell therapy represents a paradigm shift utilizing genetic medicine concepts,” Jonathon Sedgwick, vice president and global head of discovery research at AbbVie, said in a statement, adding that the Umoja partnership will allow the pharma to strengthen its oncology portfolio with next-generation CAR-T therapies and target new patient populations..

AbbVie副总裁兼发现研究全球负责人乔纳森·塞奇威克（JonathonSedgwick）在一份声明中表示：“我们认为原位CAR-T细胞疗法代表了利用遗传医学概念的范式转变，并补充说，Umoja合作伙伴关系将使制药公司能够通过下一代CAR-T疗法加强其肿瘤学组合，并针对新的患者群体。”。。

Thursday’s deals will leverage Umoja’s VivoVec gene delivery platform, which combines a proprietary third-generation lentiviral vector delivery system with a T-cell targeting and activation surface complex. According to the biotech’s website, VivoVec allows a patient’s cells to produce their own CAR-T cells..

周四的交易将利用Umoja的VivoVec基因传递平台，该平台将专有的第三代慢病毒载体传递系统与T细胞靶向和激活表面复合物相结合。根据生物技术公司的网站，VivoVec允许患者的细胞产生自己的CAR-T细胞。。

This approach potentially sidesteps several challenges associated with other CAR-T therapies including the need for lymphodepletion, the reliance on harvested autologous or donor cells and the “time lag” due to the ex vivo modification of cells, AbbVie said in its announcement.

AbbVie在其声明中表示，这种方法可能会回避与其他CAR-T疗法相关的几个挑战，包括需要淋巴清除，依赖收获的自体或供体细胞以及由于细胞的离体修饰而产生的“时滞”。

The first agreement will allow AbbVie to exclusively license Umoja’s CD19-targeting in-situ CAR-T candidates including its lead program UB-VV111, which is being assessed for hematological malignancies and is currently being prepared for an Investigational New Drug application.

第一份协议将允许AbbVie独家许可Umoja的CD19靶向原位CAR-T候选物，包括其主要计划UB-VV111，该计划正在评估血液系统恶性肿瘤，目前正在准备进行研究性新药申请。

The second deal will allow AbbVie to use VivoVec to generate up to four new in-situ CAR-T therapy candidates for yet-undisclosed discovery targets.

第二笔交易将允许AbbVie使用VivoVec为尚未公开的发现目标生成多达四个新的原位CAR-T治疗候选物。

Thursday’s dual agreements with Umoja continues AbbVie’s dealmaking spree in late 2023, which saw the pharma ink two multibillion-dollar agreements. The first was with ImmunoGen and its deep portfolio of antibody-drug conjugates (ADC), which AbbVie bought for $10.1 billion.

周四与Umoja达成的双重协议延续了AbbVie在2023年末的交易热度，该制药公司签署了两项数十亿美元的协议。第一个是免疫原及其深层抗体-药物偶联物（ADC）组合，AbbVie以101亿美元收购了该组合。

The ImmunoGen deal gives AbbVie ownership of Elahere (mirvetuximab soravtansine-gynx), which won the FDA’s accelerated approval in November 2022 for platinum-resistant ovarian cancer. In May 2023, Elahere cleared its Phase III confirmatory trial MIRASOL, positioning the ADC for full approval.

这项免疫原交易使AbbVie拥有Elahere（mirvetuximab soravtansine gynx）的所有权，Elahere于2022年11月获得了FDA对铂类耐药卵巢癌的加速批准。2023年5月，Elahere批准了其III期确认性试验MIRASOL，使ADC获得全面批准。

A week after the Immunogen buy, AbbVie dropped $8.7 billion to acquire Cerevel and its portfolio of potentially best-in-class molecules for psychiatric and neurological diseases.

购买免疫原一周后，AbbVie斥资87亿美元收购了Cerevel及其潜在的最佳精神和神经疾病分子组合。

Tristan Manalac is an independent science writer based in Metro Manila, Philippines. He can be reached at tristan@tristanmanalac.com or tristan.manalac@biospace.com.

特里斯坦·马纳拉克（TristanManalac）是一位独立的科学作家，总部位于菲律宾马尼拉。联系方式tristan@tristanmanalac.com或tristan.manalac@biospace.com.